C88.4 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]

Name of the Condition

• Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]
• A type of non-Hodgkin lymphoma that arises in tissues outside the lymph nodes, often associated with mucosa-associated lymphoid tissue (MALT), such as the stomach, salivary glands, or lungs.

Summary

Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma) is a slow-growing cancer involving the abnormal proliferation of B-cells in extranodal sites. It typically develops in tissues with MALT, such as the gastrointestinal tract, respiratory system, or salivary glands, and may be linked to chronic inflammation or infections.

Causes

The exact causes are not fully understood, but chronic infections (e.g., Helicobacter pylori in gastric MALT-lymphoma) or autoimmune conditions may trigger the development of this lymphoma by promoting B-cell proliferation in affected tissues.

Risk Factors

• Chronic infections (e.g., bacterial or viral).
• Autoimmune disorders (e.g., Sjögren syndrome, Hashimoto thyroiditis).
• Exposure to certain environmental or occupational agents.
• Age, with most cases diagnosed in adults over 50.

Symptoms

• Localized swelling or mass in the affected tissue (e.g., abdominal pain, salivary gland enlargement).
• Fatigue or unexplained weight loss.
• Symptoms related to the involved organ (e.g., dyspepsia in gastric cases, dry eyes/mouth in salivary gland cases).
• Fever or night sweats (less common).

Diagnosis

Diagnosis involves a physical exam, imaging (e.g., CT or endoscopy) to identify affected tissues, and a biopsy to confirm the presence of marginal zone B-cells. Blood tests or additional tissue analysis may be used to rule out other conditions.

Treatment Options

• Antibiotic therapy (e.g., for H. pylori-associated gastric cases).
• Radiation therapy for localized disease.
• Immunotherapy or chemotherapy for advanced or refractory cases.
• Watchful waiting for asymptomatic or slow-growing tumors.

Prognosis and Follow-Up

Prognosis is generally favorable due to the slow-growing nature of the disease, but outcomes depend on the site and extent of involvement. Regular follow-up with imaging and clinical assessments is recommended to monitor for recurrence or progression.

Complications

• Organ dysfunction due to tumor infiltration (e.g., gastric ulcers, respiratory obstruction).
• Transformation to a more aggressive lymphoma in rare cases.
• Treatment-related side effects (e.g., from radiation or chemotherapy).

Lifestyle & Prevention

• Manage chronic infections or inflammatory conditions promptly.
• Avoid known environmental triggers if applicable.
• Maintain regular medical check-ups, especially if at increased risk.

When to Seek Professional Help

Seek care if you experience persistent symptoms like unexplained swelling, organ-specific pain, or systemic signs (e.g., weight loss, fever) that do not resolve.

Tips for Medical Coders

• Use C88.4 for extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma).
• Ensure documentation specifies the extranodal site (e.g., gastric, salivary gland) and confirms MALT association when applicable.
• Differentiate from other B-cell lymphomas or extranodal lymphomas without MALT involvement.